Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04411680 · ClinicalTrials.gov registry record · Phase 2
Study of Sargramostim in Patients With COVID-19
A Phase 2 study, sponsored by Partner Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT04411680: Completed Phase 2 study, sponsored by Partner Therapeutics.
NCT04411680 is a Phase 2 study that has completed, run by Partner Therapeutics. The registered enrollment target is 123 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04411680, a Phase 2 study, has completed, sponsored by Partner Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.
Primary Outcome
The P(A-a)O2 gradient is a measure of how well the oxygen moves from the lungs into the bloodstream. Patients with a high gradient have less oxygen in the bloodstream.
Interventions
- DRUG Sargramostim
- DRUG Standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2020-08-18 |
| Est. Completion | 2021-05-19 |
| Phase | Phase 2 |
What the finished NCT04411680 record still lists
NCT04411680 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Sargramostim is the first listed.
NCT04411680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04411680 about?
NCT04411680 is a clinical study titled "Study of Sargramostim in Patients With COVID-19". The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19. Sargramostim may help the lungs recover from the effects of COVID-19, and this research study will help to find this out.
What is the current status of trial NCT04411680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2020-08-18. Estimated completion is 2021-05-19.
What interventions are being tested in trial NCT04411680?
The interventions under investigation include: Sargramostim (DRUG), Standard of care (DRUG).
Who is sponsoring clinical trial NCT04411680?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04411680's enrollment target sits among peer trials
123 564th of 2000 higher than 1,436 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI